Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

Inclusion Criteria

• •1. Willingness and ability to provide written informed consent
• •2. Willingness and ability to comply with scheduled visits and study procedures
• •3. Male or female, aged 18-85 years
• •4. Diagnosed with obstructive hypertrophic cardiomyopathy according to presence of a left ventricular wall thickness of ≥15 mm that is otherwise unexplained by abnormal loading conditions (e.g., hypertension, valvular, congenital disease) or infiltrative cardiomyopathies. Unexplained left ventricular wall thickness of ≥13 mm is sufficient for diagnosis in relatives of individuals with hypertrophic cardiomyopathy or those who are genotype positive.
• •5. Has been prescribed mavacamten consistent with US Prescribing Information
• •6. Ability and intention to adhere to oral mavacamten therapy as prescribed by treating physician for the duration of study participation
• •7. For females of reproductive potential: negative pregnancy test at screening/baseline and 12 month visits.